Accueil・Liste d'Actions・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Fermé

SecteurSoins de santé

9.66 1.15

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

9.48

Max

9.75

Chiffres clés
By Trading Economics
Revenu	800M 78M
Ventes	62M 218M
P/E Moyenne du Secteur	7.603 57.371
BPA	0.3
Marge bénéficiaire	35.92
Employés	435
EBITDA	799M 99M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+114.03% upside

Dividendes
By Acuity
Prochains Résultats	2 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	301M 2.5B
Ouverture précédente	8.51
Clôture précédente	9.66

BioCryst Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 août 2026, 19:26 UTC

BioCryst Pharmaceuticals Inc shares are trading higher, maintaining a position above the 20-day moving average and near the midpoint of their one-month range.

21 août 2026, 22:26 UTC

BioCryst Pharmaceuticals shares moved higher in after-hours trading, reaching a session high before slightly retracing. No specific news was identified to explain the movement.

20 août 2026, 20:01 UTC

Correlated Moves

Social Media

BioCryst Pharmaceuticals Inc shares are lower amid a decline in the Biotechnology sub-sector. Earlier in the session, shares rebounded from a session high.

19 août 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18 août 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14 août 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13 août 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12 août 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11 août 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10 août 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

7 août 2026, 19:56 UTC

BioCryst Pharmaceuticals is trading higher, continuing a positive trend amid easing concerns over interest rate hikes following a disappointing jobs report.

6 août 2026, 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5 août 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4 août 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 août 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 juil. 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 juil. 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 juil. 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 juil. 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27 juil. 2026, 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24 juil. 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 juil. 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 juil. 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 juil. 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Comparaison

Variation de prix

BioCryst Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

114.03% hausse

Prévisions sur 12 Mois

Moyen 20.44 USD 114.03%

Haut 32 USD

Bas 12 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.